Generated by AI
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal immunotherapies for immune and autoimmune disorders, as well as infectious diseases. The company’s platform is designed to produce high-potency antibody therapies without relying on human donors or convalescent plasma, using a proprietary approach to generate targeted immunoglobulins. Its current pipeline is centered on SAB-142, a lead product candidate being developed for autoimmune type 1 diabetes. SAB Biotherapeutics Inc. also applies its DiversitAb platform to create multi-target antibody medicines intended for difficult-to-treat conditions across immunology and infectious disease. Based in the United States, the company operates in the biotechnology sector, where it contributes to the development of next-generation antibody-based treatments for patients with significant unmet medical needs.
Website777 W 41st St.
Miami Beach, FL, 33140
United States
The latest articles about SABS.
Summary of Oct 13's posts. Generated by AI.
Summary of Jul 21's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Summary of May 7's posts. Generated by AI.
Investors talking about SABS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.